Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France) to launch Romarène®, a product derived from rosemary for the treatment of digestive disorders.
The Group launches Citrate de Betaïne®, a product used in the symptomatic treatment of dyspepsia.
The Group opens its first research facility in Les Ulis (France).
The Group enters an expansion phase with the launch of Ginkor®, Tanakan® and Smecta®. The Group creates Laboratoires Ipsen (Institute of Synthetic Products from Natural Extraction).
Ipsen initiates a partnership with Debiopharm....
The Group creates La Fondation Ipsen under the aegis of the Fondation de France. Its mission is to foster interactions between leading scientists in the field of life sciences.
Ipsen begins its development in China, with the opening of a representative office in Tianjin.
Ipsen acquires Speywood, the company that developed Dysport® for the treatment of movement disorders and various forms of muscular spasticity.
The Group launches Somatuline®, its sustained-release peptide for the treatment of acromegaly and neuroendocrine tumors in France.
Ipsen launches Forlax®, a product used for the treatment of constipation.
Ipsen opens a manufacturing facility in China to produce Smecta® for the Chinese market.
Ipsen launches Somatuline® Autogel® in the UK, France followed by many other countries, strengthening Ipsen’s competitive position. To the Group’s knowledge, Somatuline® Autogel® is the first semi-solid formulation for injection without any excipient, since the active substance controls the sustained release.
Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably Somatuline® Autogel®, in Japan and a Teijin product for the treatment of gout in Europe.
The Group opens a botulinum toxin manufacturing facility in Wrexham (United Kingdom).
Ipsen’s shares are listed on Euronext Paris. Ipsen enters into a licensing agreement with Radius through which Radius acquires the exclusive worldwide rights (excluding Japan) to develop, manufacture and distribute Ipsen’s osteoporosis proprietary molecule.
Ipsen enters into an agreement with Medicis (now Valeant) to market its botulinum toxin in aesthetic medicine indications in the US, Canada and Japan.
The Group enters into a partnership with Galderma, for the development, promotion and distribution of the Group’s botulinum toxin type A in aesthetic medicine indications.
Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego, US) aimed at improving understanding of proliferative and degenerative diseases.
Ipsen and Galderma receive collective green light for Azzalure® from 15 European countries’ Health Authorities for the granting of national marketing authorizations for the treatment of glabellar lines
Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership to create a hemophilia franchise...
Ipsen announces a new development strategy based on three pillars...
Ipsen enters into a research partnership with Oncodesign to develop new therapeutic agents against LRRK2, a gene whose mutation is involved in Parkinson's disease.
Teijin Pharma Limited and Ipsen launch of Somatuline® 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism.